Thalidomide
Recommended Oncology
Treatment of patients newly diagnosed with multiple myeloma who are ineligible for treatment with high dose chemotherapy or a stem cell transplant; and treatment of a patient newly diagnosed with multiple myeloma.
1
Submissions
2009–09
On the record
$15k–45k
ICER range
1 sourced ICER · 2009
ICER stated
Cost basis
Decisions on record
- Meeting Jul 2010 Recommended Multiple myeloma no PSD
- Meeting Mar 2010 Recommended Multiple myeloma no PSD
- Meeting Mar 2009 Recommended Anti- cancer drug
Access path
- Mar 2009Recommended · restricted
vs For ineligible HDC/SCT patients: melphalan and prednisone…
- PBS listing
RecommendedDeferredNot recommended
Cost-effectiveness
ICER uncertainICER / price too high
Decision context
Populationpatients newly diagnosed with multiple myeloma who are ineligible for treatment with high dose chemotherapy or a stem cell transplant; and patients newly diagnosed with multiple myeloma
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Mar 2009 | Recommended · restricted | For ineligible HDC/SCT patients: melphalan and prednisone alone (MP). For eligible HDC/SCT patients: vincristine, adriam | $15k–45k | RCT · OS, PFS, Response rate (CR+VGPR+PR) |